

References

- Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. *Lancet Oncol* 2010;11(1):55-65.
- Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. *N Engl J Med* 2000;342:1462-70.
- Grant RM, Lama JR, Anderson PL, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med* 2010;363(27):2587-99.
- Murphy S. Optimal dynamic treatment regimes. *JRSS B* 2003;65(2):331-355.
- Tian L, Alizadeh A. A., Gentles A. J. and Tibshirani R. A Simple Method for Estimating Interactions Between a Treatment and a Large Number of Covariates. *J Am Stat Assoc* 2014;109(508):1517-32.

- Luedtke, A. R., & van der Laan, M. J. (2016). Super-learning of an optimal dynamic treatment rule. *Int J Biostat*, 12(1), 305332.
- VanderWeele, Tyler J., et al. "Selecting optimal subgroups for treatment using many covariates." arXiv preprint arXiv:1802.09642 (2018).
- Zhang B, Tsiatis AA, Laber EB, et al. A robust method for estimating optimal treatment regimes. *Biometrics* 2012;68(4):1010-1018.
- Zhao Y, Zeng D, Rush AJ, et al. Estimating individualized treatment rules using Outcome Weighted Learning. *J Am Stat Assoc* 2012;107(449):1106-1118.
- Zhou X, Mayer-Hamblett N, Khan U, and Kosorok M. R. Residual Weighted Learning for Estimating Individualized Treatment Rules. *J Am Stat Assoc* 2017;112:169–87.
- Qian, M. and Murphy, S. (2011). Performance guarantees for individualized treatment rules. *The Annals of Statistics*, 39, 11801210.
- Murphy, S. A., et al. "Developing adaptive treatment strategies in substance abuse research." *Drug and alcohol dependence* 88 (2007): S24-S30.

Janes H, Brown MD, Pepe MS, et al. An approach to evaluating and comparing biomarkers for patient treatment selection. *Int J Biostat* 2014;10(1):99–121.

Song X, Pepe MS. Evaluating markers for selecting a patient's treatment. *Biometrics* 2004;60(4):874–83.

Gunter L, Zhu J, Murphy S. Variable selection for qualitative interactions in personalized medicine while controlling the family-wise error rate. *J Biopharm Stat* 2011;21(6):1063–78.

Janes H, Pepe MS, Bossuyt PM, et al. Measuring the performance of markers for guiding treatment decisions. *Ann Intern Med* 2011;154(4):253–9.

Hernn MA, Robins JM. Causal Inference. Boca Raton: Chapman & Hall/CRC, forthcoming.

Robins JM, Hernn MA, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiology* 2000;11(5):550–60.

van der Laan, MJ, and Luedtke, AR. "Targeted learning of the mean outcome under an optimal dynamic treatment rule." *Journal of causal inference* 3.1 (2015): 61-95.

Huang Y, Gilbert PB, Janes H. Assessing treatment-selection markers using a potential outcomes framework. *Biometrics* 2012;68(3):687–96.

Zhang Z, Nie L, Soon G, et al. The use of covariates and random effects in evaluating predictive biomarkers under a potential outcomes framework. *Ann Appl Stat* 2014;8:2336-2355.

Sitlani CM, Heagerty PJ. Analyzing longitudinal data to characterize the accuracy of markers used to select treatment. *Stat Med* 2014;33(17):2881-2896.

Simon R. Sensitivity, specificity, PPV, NPV for predictive biomarkers. *J Natl Cancer Inst* 2015;107(8). pii: djv153.

Vickers AJ, Kattan MW, Daniel S. Method for evaluating prediction models that apply the results of randomized trials to individual patients. *Trials* 2007;8:14.

Janes H, Pepe MS, Huang Y. A framework for evaluating markers used to select patient treatment. *Med Decis Making* 2014;34(2):159–67.

Sargent D, Conley B, Allegra C, et al. Clinical trial designs for predictive marker validation in cancer treatment trials. *J Clin Onc* 2005;23:2020–2027.

Simon, RM, Paik, S, and Hayes, DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. *J Natl Cancer Inst* 2010;101:1446–52.

Janes H, Brown MD, Pepe MS. Designing a study to evaluate the benefit of a biomarker for selecting patient treatment. *Stat Med* 2015;34(27):3503–15.

Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. *Clin Ca Res* 2004;10:6759–6763.

Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. *J Clin Onc* 2009;24(24):4027–4034.

Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* 2005;353:1673–1684.

Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A Phase III trial in non-small-cell lung cancer. *J Clin Oncol* 2007;25:2747–2754.

Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. *Clin Ca Res* 2005;11(21):7872–8.

Friedlin B, Jiang W, Simon R. The cross-validated adaptive signature design. *Clin Ca Res* 2010;16:691–698.

Cox DR. Regression models and life-tables. *J Royal Stat Soc Series B* 1972;24(2):187–220.

Rubin, Daniel, and Mark J. van der Laan. "A doubly robust censoring unbiased transformation." *The international journal of biostatistics* 3.1 (2007).

Goldberg Y and Kosorok MR. Q-learning with censored data. *Ann of Stat* 2012;40:529–560.

Murphy SA. An experimental design for the development of adaptive treatment strategies. *Stat Med* 2005;24:1455–81.

Zhao YQ, Zheng D, Laber B, et al. Doubly robust learning for estimating individualized treatment with censored data. *Biometrika* 2015;102:151–68.

Bang, Heejung, and James M. Robins. "Doubly robust estimation in missing data and causal inference models." *Biometrics* 61.4 (2005): 962-973.